Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer

Abstract Background In the phase 3 EMPOWER‐Cervical 1/GOG‐3016/ENGOT‐cx9 study, cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first‐line platinum‐based chemotherapy. We present a post hoc sub...

Full description

Saved in:
Bibliographic Details
Main Authors: Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, Masao Okadome, Kan Yonemori, Harushige Yokota, Ignace Vergote, Bradley J. Monk, Krishnansu S. Tewari, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil, Anne Paccaly, Kazuhiro Takehara, Tomoka Usami, Yoichi Aoki, Nao Suzuki, Yoichi Kobayashi, Yoshio Yoshida, Hidemichi Watari, Frank Seebach, Israel Lowy, Melissa Mathias, Matthew G. Fury, Ana Oaknin
Format: Article
Language:English
Published: Wiley 2024-09-01
Series:Cancer Medicine
Subjects:
cemiplimab
cervical cancer
chemotherapy
immunotherapy
programmed cell death‐1
Online Access:https://doi.org/10.1002/cam4.70236
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70236

Similar Items